These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Atopic dermatitis in the US military. Riegleman KL; Farnsworth GS; Wong EB Cutis; 2019 Sep; 104(3):144-147. PubMed ID: 31675397 [TBL] [Abstract][Full Text] [Related]
23. Research Techniques Made Simple: Mouse Models of Atopic Dermatitis. Kim D; Kobayashi T; Nagao K J Invest Dermatol; 2019 May; 139(5):984-990.e1. PubMed ID: 31010529 [TBL] [Abstract][Full Text] [Related]
24. Approach to the Assessment and Management of Adult Patients With Atopic Dermatitis: A Consensus Document. Section II: Tools for Assessing the Severity of Atopic Dermatitis. Gooderham MJ; Bissonnette R; Grewal P; Lansang P; Papp KA; Hong CH J Cutan Med Surg; 2018; 22(1_suppl):10S-16S. PubMed ID: 30439297 [TBL] [Abstract][Full Text] [Related]
25. Measuring atopic eczema symptoms in clinical practice: The first consensus statement from the Harmonising Outcome Measures for Eczema in clinical practice initiative. Leshem YA; Chalmers JR; Apfelbacher C; Furue M; Gerbens LAA; Prinsen CAC; Schmitt J; Spuls PI; Thomas KS; Williams HC; Simpson EL; J Am Acad Dermatol; 2020 May; 82(5):1181-1186. PubMed ID: 31926221 [TBL] [Abstract][Full Text] [Related]
35. The Eczema Area and Severity Index-A Practical Guide. Hanifin JM; Baghoomian W; Grinich E; Leshem YA; Jacobson M; Simpson EL Dermatitis; 2022 May-Jun 01; 33(3):187-192. PubMed ID: 35594457 [TBL] [Abstract][Full Text] [Related]
36. Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting. Thomas KS; Apfelbacher CA; Chalmers JR; Simpson E; Spuls PI; Gerbens LAA; Williams HC; Schmitt J; Gabes M; Howells L; Stuart BL; Grinich E; Pawlitschek T; Burton T; Howie L; Gadkari A; Eckert L; Ebata T; Boers M; Saeki H; Nakahara T; Katoh N Br J Dermatol; 2021 Jul; 185(1):139-146. PubMed ID: 33393074 [TBL] [Abstract][Full Text] [Related]
37. TREatment of ATopic eczema (TREAT) Registry Taskforce: consensus on how and when to measure the core dataset for atopic eczema treatment research registries. Vermeulen FM; Gerbens LAA; Bosma AL; Apfelbacher CJ; Irvine AD; Arents BWM; Barbarot S; Deleuran M; Eichenfield LF; Manca A; Schmitt J; Vestergaard C; Wall D; Weidinger S; Middelkamp-Hup MA; Spuls PI; Flohr C; Br J Dermatol; 2019 Sep; 181(3):492-504. PubMed ID: 30719709 [TBL] [Abstract][Full Text] [Related]
38. Atopic dermatitis and non-atopic hand eczema have similar negative impacts on quality of life: implications for clinical significance. Chen YC; Wu CS; Lu YW; Li WC; Ko YC; Yu HS; Chen GS; Lan CC Acta Derm Venereol; 2013 Nov; 93(6):749-50. PubMed ID: 23532329 [No Abstract] [Full Text] [Related]
39. Severity strata of patient-oriented eczema measure scores in patients with atopic dermatitis in Mongolia. Ulzii D; Nakahara T; Furue M; Byamba K; Kido-Nakahara M Int J Dermatol; 2022 Dec; 61(12):e469-e472. PubMed ID: 35398893 [No Abstract] [Full Text] [Related]
40. Comparison of Patient-Oriented Eczema Measure and Patient-Oriented Scoring Atopic Dermatitis vs Eczema Area and Severity Index and other measures of atopic dermatitis: A validation study. Silverberg JI; Lei D; Yousaf M; Janmohamed SR; Vakharia PP; Chopra R; Chavda R; Gabriel S; Patel KR; Singam V; Kantor R; Hsu DY Ann Allergy Asthma Immunol; 2020 Jul; 125(1):78-83. PubMed ID: 32199977 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]